Sophiris reports patient death in prostate cancer trial

Sophiris Bio Inc. (NASDAQ:SPHS) reported a patient death in an open-label, U.S. and U.K. Phase IIb trial evaluating topsalysin (PRX302) to treat localized prostate cancer.

The company said it is

Read the full 292 word article

User Sign In